Effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos in vitro

被引:74
作者
Longo, M
Zanoncelli, S
Manera, D
Brughera, M
Colombo, P
Lansen, J
Mazué, G
Gomes, M
Taylor, WRJ
Olliaro, P
机构
[1] Nerviano Med Sci, Dept Preclin Dev, I-20014 Milan, Italy
[2] Fermes Bosne, F-39230 Mantry, France
[3] WHO, UNICEF, UNDP, World Bank,Special Programme Res & Training Trop, CH-1211 Geneva, Switzerland
[4] UCL Royal Free & Univ Coll, Sch Med, Ctr Infect Dis, Windeyer Inst Med Sci, London, England
[5] Univ Oxford, Ctr Trop Med & Vaccinol, Churchill Hosp, Oxford OX1 2JD, England
关键词
dihydroartemisinin; malaria; antimalarial drug; embryotoxicity; whole embryo culture; yolk sac hematopoiesis; yolk sac angiogenesis;
D O I
10.1016/j.reprotox.2005.05.005
中图分类号
Q [生物科学];
学科分类号
07 [理学]; 0710 [生物学]; 09 [农学];
摘要
Artemisinin derivatives are not currently recommended for use during the first trimester of pregnancy because they cause embryo death and some abnormalities in early pregnancy in animals. We studied the effects of dihydroartemisinin (DHA) in rat whole embryo cultures (WEC). DHA was added to the culture medium for the entire 48-h culture, 1.5 h at the beginning or at the end of the culture at 0.01-2 mu g/mL. DHA affected primarily red blood cells during yolk sac hematopoiesis. Higher concentrations and longer exposure inhibited angiogenesis. Tissue damage (cell deaths) and effects on embryo morphology (neural tube, branchial arches, somites and caudal region defects) were attributed to these events. The viability of severely affected embryos beyond the 48-h assay is uncertain. These results help explain findings from animal data and provide evidence that the yolk sac is highly susceptible to artemisinin compounds. Extrapolating results to pregnant women exposed in the first trimester remains difficult. Pharmacovigilance and further studies of the mechanism of damage are needed. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:83 / 93
页数:11
相关论文
共 36 条
[1]
Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8
[2]
[Anonymous], 2004, STRATEGIC FRAMEWORK
[3]
Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria [J].
Binh, TQ ;
Ilett, KF ;
Batty, KT ;
Davis, TME ;
Hung, NC ;
Powell, SM ;
Thu, LTA ;
Van Thien, H ;
Phuöng, HL ;
Phuong, VDB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (06) :541-546
[4]
Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine [J].
Brockman, A ;
Price, RN ;
van Vugt, M ;
Heppner, DG ;
Walsh, D ;
Sookto, P ;
Wimonwattrawatee, T ;
Looareesuwan, S ;
White, NJ ;
Nosten, F .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2000, 94 (05) :537-544
[5]
QUANTITATION OF RAT EMBRYONIC-DEVELOPMENT INVITRO - A MORPHOLOGICAL SCORING SYSTEM [J].
BROWN, NA ;
FABRO, S .
TERATOLOGY, 1981, 24 (01) :65-78
[6]
Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1 [J].
Chen, HH ;
Zhou, HJ ;
Wu, GD ;
Lou, XE .
PHARMACOLOGY, 2004, 71 (01) :1-9
[7]
CHEN LJ, 1984, ACTA PHARMACOL SIN, V5, P118
[8]
China Cooperative Research Group on Qinghaosu and its Derivatives as Antimalarials, 1982, J TRADIT CHIN MED, V2, P31
[9]
Spatial and temporal ontogenies of glutathione peroxidase and glutathione disulfide reductase during development of the prenatal rat [J].
Choe, H ;
Hansen, JM ;
Harris, C .
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2001, 15 (04) :197-206
[10]
Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit [J].
Clark, RL ;
White, TEK ;
Clode, SA ;
Gaunt, I ;
Winstanley, P ;
Ward, SA .
BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2004, 71 (06) :380-394